PMID- 32448653
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 52
IP  - 8
DP  - 2020 Oct
TI  - Angiotensin II Type 1 Receptor Expression in Renal Transplant Biopsies and 
      Anti-AT1R Antibodies in Serum Indicates the Risk of Transplant Loss.
PG  - 2299-2304
LID - S0041-1345(19)31845-7 [pii]
LID - 10.1016/j.transproceed.2020.01.126 [doi]
AB  - The manifestation of anti-angiotensin II type 1 receptor (AT1R) antibodies is 
      considered a risk factor for transplant injury; however, the occurrence of 
      angiotensin II type 1 (AT1)-Receptor expression in renal transplant biopsy may 
      help to predict transplant loss. The aim of our study was to evaluate the 
      expression of AT1-Receptors together with their antibodies and assess the risk of 
      transplant loss in patients who had a renal transplant indication biopsy. 
      METHODS: AT1-Receptor immunoreactivity was analyzed in renal transplant biopsies. 
      Additionally, we analyzed the presence of anti-AT1R antibodies in these patients 
      using the enzyme-linked immunosorbent assay (ELISA) method. A result >/= 10 was 
      assessed as positive. An immunohistochemical evaluation of AT1-Receptor 
      expression was performed on 4 mum-thick paraffin sections mounted on salinized 
      slides. RESULTS: We checked 156 samples of biopsies for the immunoreactivity of 
      the AT1-Receptor. Additionally, we analyzed the presence of anti-AT1R antibodies 
      in these patients using the ELISA method. A group of 67 patients had positive 
      AT1-Receptor expression, and 16 patients had positive anti-AT1R antibodies 
      (R+Ab+) results. A group of 89 patients had no expression of AT1-Receptor, among 
      which 51 had also no anti-AT1R (R-Ab-). One-year postbiopsy graft loss in the 
      R+Ab+ patients was 37% (6/16) compared to 10% (7/69) in the R-Ab- patients 
      (P = .006). Two-year and 3-year graft loss was 43% versus 17% and 50% versus 21%, 
      respectively. CONCLUSIONS: The presence of anti-AT1R antibodies in serum together 
      with the expression of AT1-Receptor in transplant biopsies was associated with a 
      significantly higher graft loss. The relevance of AT1-Receptor expression 
      analyzed together with anti-AT1R antibodies should be considered for better 
      transplant immunologic risk assessment.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Sas-Strozik, Agnieszka
AU  - Sas-Strozik A
AD  - Department of Nephrology and Transplantation Medicine, Wroclaw Medical 
      University, Wroclaw, Poland. Electronic address: a_sas@op.pl.
FAU - Donizy, Piotr
AU  - Donizy P
AD  - Department of Pathomorphology and Oncological Cytology, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Koscielska-Kasprzak, Katarzyna
AU  - Koscielska-Kasprzak K
AD  - Research Laboratory, Wroclaw Medical University, Wroclaw, Poland.
FAU - Kaminska, Dorota
AU  - Kaminska D
AD  - Department of Nephrology and Transplantation Medicine, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Gawlik, Kamila
AU  - Gawlik K
AD  - Department of Nephrology and Transplantation Medicine, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Mazanowska, Oktawia
AU  - Mazanowska O
AD  - Department of Nephrology and Transplantation Medicine, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Madziarska, Katarzyna
AU  - Madziarska K
AD  - Department of Nephrology and Transplantation Medicine, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Halon, Agnieszka
AU  - Halon A
AD  - Department of Pathomorphology and Oncological Cytology, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Krajewska, Magdalena
AU  - Krajewska M
AD  - Department of Nephrology and Transplantation Medicine, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Banasik, Miroslaw
AU  - Banasik M
AD  - Department of Nephrology and Transplantation Medicine, Wroclaw Medical 
      University, Wroclaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Autoantibodies)
RN  - 0 (Receptor, Angiotensin, Type 1)
SB  - IM
MH  - Adult
MH  - Autoantibodies/*blood/immunology
MH  - Biopsy
MH  - Female
MH  - Graft Rejection/*immunology
MH  - Humans
MH  - *Kidney Transplantation/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Receptor, Angiotensin, Type 1/*immunology
MH  - Risk Assessment
MH  - Transplants/immunology
EDAT- 2020/05/26 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/01/26 00:00 [accepted]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - S0041-1345(19)31845-7 [pii]
AID - 10.1016/j.transproceed.2020.01.126 [doi]
PST - ppublish
SO  - Transplant Proc. 2020 Oct;52(8):2299-2304. doi: 
      10.1016/j.transproceed.2020.01.126. Epub 2020 May 21.